• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The Clinical Impact of Synchronous and Metachronous Other Primary Cancer in Gastric Cancer Patients Who Receive Curative Treatment.根治性治疗的胃癌患者中同时性和异时性其他原发性癌症的临床影响。
In Vivo. 2022 Sep-Oct;36(5):2514-2520. doi: 10.21873/invivo.12987.
2
Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer.胃癌根治性切除术后异时性多原发癌的预测。
BMC Cancer. 2013 Aug 23;13:394. doi: 10.1186/1471-2407-13-394.
3
Synchronous and metachronous neoplasms in gastric cancer patients: a 23-year study.胃癌患者的同步和异时性肿瘤:一项为期23年的研究。
World J Gastroenterol. 2014 Jun 21;20(23):7480-7. doi: 10.3748/wjg.v20.i23.7480.
4
Features of synchronous and metachronous dual primary gastric and colorectal cancer.同步性和异时性胃结直肠癌双原发癌的特征
World J Gastrointest Oncol. 2023 Nov 15;15(11):1864-1873. doi: 10.4251/wjgo.v15.i11.1864.
5
Impact of Synchronous Versus Metachronous Onset of Colorectal Peritoneal Metastases on Survival Outcomes After Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Multicenter, Retrospective, Observational Study.结直肠腹膜转移同步与异时发生对细胞减灭术(CRS)联合腹腔热灌注化疗(HIPEC)后生存结局的影响:一项多中心、回顾性、观察性研究。
Ann Surg Oncol. 2019 Jul;26(7):2210-2221. doi: 10.1245/s10434-019-07294-y. Epub 2019 Mar 15.
6
The Clinical Impact of Other Primary Cancer in Patients Who Received Curative Treatment for Esophageal Cancer.接受食管癌根治性治疗的患者中其他原发性癌症的临床影响。
Anticancer Res. 2022 Nov;42(11):5635-5641. doi: 10.21873/anticanres.16072.
7
Multiple Pulmonary Resections for Synchronous and Metachronous Lung Cancer at Two Chinese Centers.多中心回顾性分析两家中心同期和异时性肺癌肺切除术后生存情况。
Ann Thorac Surg. 2020 Mar;109(3):856-863. doi: 10.1016/j.athoracsur.2019.09.088. Epub 2019 Nov 22.
8
Prognostic significance of intestinal claudins in high-risk synchronous and metachronous multiple gastric epithelial neoplasias after initial endoscopic submucosal dissection.初始内镜黏膜下剥离术后高危同步和异时性多发胃上皮性肿瘤中肠紧密连接蛋白的预后意义
Pathol Int. 2008 Jun;58(6):371-7. doi: 10.1111/j.1440-1827.2008.02238.x.
9
Clinicopathologic features of gastric cancer with synchronous and metachronous colorectal cancer in Korea: are microsatellite instability and p53 overexpression useful markers for predicting colorectal cancer in gastric cancer patients?韩国胃癌合并同时性和异时性结直肠癌的临床病理特征:微卫星不稳定性和p53过表达是否为预测胃癌患者发生结直肠癌的有用标志物?
Gastric Cancer. 2016 Jul;19(3):798-807. doi: 10.1007/s10120-015-0552-6. Epub 2015 Oct 7.
10
[Synchronous or metachronous primary cancers of other organs in 74 patients with gastric cancer].74例胃癌患者中其他器官的同步或异时原发性癌
Zhonghua Wei Chang Wai Ke Za Zhi. 2010 Feb;13(2):125-8.

引用本文的文献

1
Synchronous gastric and ovarian cancer successfully treated with FOLFOX therapy: a case report and review of the literature.采用FOLFOX方案成功治疗同步性胃癌和卵巢癌:1例病例报告及文献复习
Int Cancer Conf J. 2024 Aug 1;13(4):427-432. doi: 10.1007/s13691-024-00704-3. eCollection 2024 Oct.
2
Colonoscopy plays an important role in detecting colorectal neoplasms in patients with gastric neoplasms.结肠镜检查在检测胃肿瘤患者的结直肠肿瘤方面发挥着重要作用。
World J Gastrointest Oncol. 2024 Jan 15;16(1):133-143. doi: 10.4251/wjgo.v16.i1.133.
3
Risk and prediction of multiple primary malignancies after early gastric cancer.早期胃癌后多原发性恶性肿瘤的风险与预测
Front Oncol. 2023 Jul 25;13:1205358. doi: 10.3389/fonc.2023.1205358. eCollection 2023.

本文引用的文献

1
Gastric cancer.胃癌。
Lancet. 2020 Aug 29;396(10251):635-648. doi: 10.1016/S0140-6736(20)31288-5.
2
Effects of nutritional interventions on nutritional status in patients with gastric cancer: A systematic review and meta-analysis of randomized controlled trials.营养干预对胃癌患者营养状况的影响:一项随机对照试验的系统评价和荟萃分析。
Clin Nutr ESPEN. 2020 Aug;38:28-42. doi: 10.1016/j.clnesp.2020.05.007. Epub 2020 Jun 16.
3
Japanese gastric cancer treatment guidelines 2018 (5th edition).《日本胃癌治疗指南2018(第5版)》
Gastric Cancer. 2021 Jan;24(1):1-21. doi: 10.1007/s10120-020-01042-y. Epub 2020 Feb 14.
4
Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial.多西他赛联合口服氟嘧啶可提高 III 期胃癌患者的疗效:JACCRO GC-07 随机对照试验的中期分析。
J Clin Oncol. 2019 May 20;37(15):1296-1304. doi: 10.1200/JCO.18.01138. Epub 2019 Mar 29.
5
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
6
Controlling Nutritional Status (CONUT) score is a prognostic marker for gastric cancer patients after curative resection.控制营养状况(CONUT)评分是胃癌患者根治性切除术后的预后标志物。
Gastric Cancer. 2018 Mar;21(2):204-212. doi: 10.1007/s10120-017-0744-3. Epub 2017 Jun 27.
7
Adjuvant therapy for locally advanced gastric cancer.局部晚期胃癌的辅助治疗。
Surg Today. 2017 Nov;47(11):1295-1302. doi: 10.1007/s00595-017-1493-y. Epub 2017 Mar 1.
8
Global cancer statistics, 2012.全球癌症统计数据,2012 年。
CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262. Epub 2015 Feb 4.
9
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.卡培他滨联合奥沙利铂辅助治疗 D2 胃切除术后胃癌(CLASSIC):一项开放标签、随机、3 期临床试验的 5 年随访结果。
Lancet Oncol. 2014 Nov;15(12):1389-96. doi: 10.1016/S1470-2045(14)70473-5. Epub 2014 Oct 15.
10
Neoadjuvant chemotherapy for gastric cancer in Japan: a standing position by comparing with adjuvant chemotherapy.日本胃癌的新辅助化疗:与辅助化疗相比的立场。
Surg Today. 2014 Jan;44(1):11-21. doi: 10.1007/s00595-013-0529-1. Epub 2013 Mar 19.

根治性治疗的胃癌患者中同时性和异时性其他原发性癌症的临床影响。

The Clinical Impact of Synchronous and Metachronous Other Primary Cancer in Gastric Cancer Patients Who Receive Curative Treatment.

机构信息

Department of Surgery, Yokohama City University, Yokohama, Japan;

Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.

出版信息

In Vivo. 2022 Sep-Oct;36(5):2514-2520. doi: 10.21873/invivo.12987.

DOI:10.21873/invivo.12987
PMID:36099136
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9463937/
Abstract

BACKGROUND/AIM: The present study evaluated the clinical characteristics and prognostic factors of gastric cancer (GC) patients with synchronous and metachronous other primary cancer who received curative treatment for GC.

PATIENTS AND METHODS

The study included 244 patients who underwent curative treatment for GC between 2005 and 2018. The risk factors for the overall survival (OS) and recurrence-free survival (RFS) were identified.

RESULTS

A total of 244 patients were included in this study. Among them, 58 patients were diagnosed with synchronous and metachronous other primary cancer. When comparing the patient background characteristics and clinical course between GC patients without and with synchronous and metachronous other primary cancer, the background, postoperative surgical complications, and details of adjuvant treatment were similar between the two groups. The 3- and 5-year OS rates in GC patients with synchronous and metachronous other primary cancer were 69.7% and 48.0%, respectively, while those in patients without synchronous and metachronous other primary cancer were 80.6% and 74.3%, respectively, showing a statistically significant difference (p<0.001) The synchronous and metachronous other primary cancer status was included in the final multivariate analysis model (hazard ratio=2.201; 95% confidence interval=1.229-3.942; p=0.008).

CONCLUSION

Synchronous and metachronous other primary cancer status is a prognostic factor in GC patients. Therefore, synchronous and metachronous other primary cancer patients need both other primary cancer and GC follow-up to improve their survival.

摘要

背景/目的:本研究评估了接受 GC 根治性治疗的同时性和异时性多原发癌胃癌(GC)患者的临床特征和预后因素。

患者与方法

本研究纳入了 2005 年至 2018 年间接受 GC 根治性治疗的 244 例患者。确定了总生存期(OS)和无复发生存期(RFS)的危险因素。

结果

本研究共纳入 244 例患者。其中,58 例患者被诊断为同时性和异时性多原发癌。在比较 GC 患者与无同时性和异时性多原发癌患者的背景特征和临床过程时,两组患者的背景、术后手术并发症和辅助治疗细节相似。同时性和异时性多原发癌 GC 患者的 3 年和 5 年 OS 率分别为 69.7%和 48.0%,而无同时性和异时性多原发癌患者的 3 年和 5 年 OS 率分别为 80.6%和 74.3%,差异有统计学意义(p<0.001)。同时性和异时性多原发癌状态被纳入最终多变量分析模型(风险比=2.201;95%置信区间=1.229-3.942;p=0.008)。

结论

同时性和异时性多原发癌状态是 GC 患者的预后因素。因此,同时性和异时性多原发癌患者需要同时关注其他原发性癌症和 GC 的随访,以提高其生存率。